Navigation Links
Can Aβ worsen cognitive impairment following cerebral ischemia-reperfusion injury?
Date:11/1/2013

Amyloid β-peptide, a major component of senile plaques in Alzheimer's disease, has been impli-cated in neuronal cell death and cognitive impairment. Recently, studies have shown that the pathogenesis of cerebral ischemia is closely linked with Alzheimer's disease. According to a study, administration of amyloid β-peptide could further aggravate impairments to learning and memory and neuronal cell death in the hippocampus of rats subjected to cerebral ischemia-reperfusion injury. The synergistic effect of amyloid β-peptide and cerebral ischemia-reperfusion injury exacerbated nerve damage by inducing glycogen synthase kinase 3β and protein phosphatase 2A activity, which resulted in the phosphorylation of tau protein. This study by Dr. Bo Song and team from Research Center of Stem Cells and Regenerative Medicine, School of Medicine, Tsinghua University, China was published in the Neural Regeneration Research (Vol. 8, No. 26, 2013)


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related biology news :

1. Gum disease found to worsen infection in animal model of AIDS
2. Food contaminants worsen metabolic problems in obese mice
3. Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice
4. Researchers develop ginseng-fortified milk to improve cognitive function
5. Piglets in mazes provide insights into human cognitive development
6. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
7. Brain training may lessen cognitive impairments associated with coronary bypass surgery
8. Cannabis use mimics cognitive weakness that can lead to schizophrenia
9. Even the smallest stroke can damage brain tissue and impair cognitive function
10. Cognitive deficits from concussions still present after 2 months
11. Induction of mild inflammation leads to cognitive deficits related to schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Can Aβ worsen cognitive impairment following cerebral ischemia-reperfusion injury?
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
Breaking Biology Technology: